Motexafin Gadolinium

Motexafin Gadolinium (MGd)

MGd is a radiation and chemotherapy sensitizing agent with a novel mechanism of action. CloseMechanism of Action

The biological and chemical explanation for how a drug works.

MGd is designed to accumulate selectively in cancer cells. Once inside cancer cells, MGd in combination with radiation induces apoptosis CloseApoptosis

Programmed cell death or suicide that results from interrupted cellular functions.

by disrupting redox-dependent pathways. CloseRedox-dependent pathways

A addition of negative charge to oxygen that triggers specific chemical reactions to take place within the cell.

We believe MGd has the potential to be used for treating many types of cancer in combination with other treatments such as chemotherapy, targeted therapy or radiation therapy. The National Cancer Institute (NCI) is currently sponsoring two Phase II trials which have and continue to provide valuable developmental insights and directions.

 

Animation of MGd

Patents

Motexafin gadolinium (MGd) has an extensive portfolio of issued patents and pending non-provisional patent applications claiming composition of matter, synthesis/manufacturing, formulation, and methods of use. These are expected to provide commercial protection for MGd to at least 2025 in the US, UK and other international markets, which are subject to patent term extensions.

Partnering

Pharmacyclics will be seeking strategic pharma biotech partnership(s) to further develop and commercialize MGd.